Expand all sections

Pembrolizumab / vibostolimab

Extended indication in combination with etoposide and platinum chemotherapy, is indicated for the first line treatment o
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Pembrolizumab / vibostolimab
Domain Oncology
Reason of inclusion New medicine (specialité)
Main indication Lung cancer
Extended indication in combination with etoposide and platinum chemotherapy, is indicated for the first line treatment of adults with extensive stage small cell lung cancer (ES SCLC)
Manufacturer MSD
Portfolio holder MSD
Route of administration Intravenous
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity New therapeutical formulation
ATMP No
Submission date January 2025
Expected Registration 2025
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Current treatment options none, atezolizumab is not reimbursed in NL
Therapeutic value No estimate possible yet
Substantiation De studie is gestopt vanwege bijwerkingen en resultaten.
Duration of treatment Maximal 2 year / years
Frequency of administration 1 times every 3 weeks
Dosage per administration 200 mg / 200mg
References NCT05224141

Expected patient volume per year

Patient volume

< 1,160

Market share is generally not included unless otherwise stated.
References 1: NKR2021.
Additional remarks In 2021 waren er in totaal 1.646 patiënten met kleincellig longcarcinoom. Hiervan betrof het in 1.160 patiënten met een stadium 4 carcinoom.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.